The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population
Open accessAbstract
Background: Among patients with clinically manifest vascular disease, the risk of recurrent vascular events is likely to vary. We assessed the distribution of estimated 10-year risk of recurrent vascular events in a secondary prevention population. We also estimated the potential risk reduction and residual risk that can be achieved if patients reach guideline-recommended risk factor targets. Methods: The SMART score (Second Manifestations of Arterial Disease) for 10-year risk of myocardial infarction, stroke, or vascular death was applied to 6904 patients with vascular disease. The risk score was externally validated in 18 436 patients with various manifestations of vascular disease from the TNT (Treating to New Targets), IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering), SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels), and CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events) trials. The residual risk at guideline-recommended targets was estimated by applying relative risk reductions from meta-analyses to the estimated risk for targets for systolic blood pressure, low-density lipoprotein cholesterol, smoking, physical activity, and use of antithrombotic agents. Results: The external performance of the SMART risk score was reasonable, apart from overestimation of risk in patients with 10-year risk >40%. In patients with various manifestations of vascular disease, median 10-year risk of a recurrent major vascular event was 17% (interquartile range, 11%–28%), varying from <10% in 18% to >30% in 22% of the patients. If risk factors were at guideline-recommended targets, the residual 10-year risk would be <10% in 47% and >30% in 9% of the patients (median, 11%; interquartile range, 7%–17%). Conclusions: Among patients with vascular disease, there is very substantial variation in estimated 10-year risk of recurrent vascular events. If all modifiable risk factors were at guideline-recommended targets, half of the patients would have a 10-year risk <10%. These data suggest that even with optimal treatment, many patients with vascular disease will remain at >20% and even >30% 10-year risk, clearly delineating an area of substantial unmet medical need.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Smoking cessation for the secondary prevention of coronary heart disease
Critchley, J. A., & Capewell, S. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003041.pub2 · Cited by 342
RetractedSmoking cessation for the secondary prevention of coronary heart disease
Critchley, J., & Capewell, S. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003041 · Cited by 63
RetractedEuropean Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationCardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Dennis, M. S. (1996) · The Lancet · Cited by 2,728
Review: a gentle introduction to imputation of missing values.
Donders, A. R. T., van der Heijden, G. J. M. G., Stijnen, T., & Moons, K. G. M. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.014 · Cited by 2,582
Smith, S. C., Allen, J., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L., Jones, D., Krumholz, H. M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174516 · Cited by 2,104
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Cardiovascular disease in Europe: epidemiological update
Nichols, M., Townsend, N., Scarborough, P., & Rayner, M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht356 · Cited by 1,343
Cardiovascular disease in Europe 2014: epidemiological update
Nichols, M., Townsend, N., Scarborough, P., & Rayner, M. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu299 · Cited by 1,294
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Horton, N. J., & Kleinman, K. P. (2007) · The American Statistician · doi:10.1198/000313007x172556 · Cited by 786
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
Graham, I. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.024 · Cited by 722
Chow, C. K., Jolly, S., Rao-Melacini, P., Fox, K. A. A., Anand, S. S., & Yusuf, S. (2010) · Circulation · doi:10.1161/circulationaha.109.891523 · Cited by 719
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Second Manifestations of ARTerial disease (SMART) study: Rationale and design
Simons, P. C. G., Algra, A., van de Laak, M. F., Grobbee, D. E., & van der Graaf, Y. (1999) · European Journal of Epidemiology · doi:10.1023/a:1007621514757 · Cited by 366
Self-citationBlood Pressure Lowering Treatment Trialists' Collaboration (2013) · BMJ · doi:10.1136/bmj.f5680 · Cited by 263
Dorresteijn, J. A. N., Visseren, F. L. J., Wassink, A. M. J., Gondrie, M. J. A., Steyerberg, E. W., Ridker, P. M., Cook, N. R., van der Graaf, Y., & on behalf of the SMART Study Group (2013) · Heart · doi:10.1136/heartjnl-2013-303640 · Cited by 260
Self-citationAn International Model to Predict Recurrent Cardiovascular Disease
Wilson, P. W. F., D'Agostino, R., Bhatt, D. L., Eagle, K., Pencina, M. J., Smith, S. C., Alberts, M. J., Dallongeville, J., Goto, S., Hirsch, A. T., et al. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.01.014 · Cited by 238
Kodama, S., Tanaka, S., Heianza, Y., Fujihara, K., Horikawa, C., Shimano, H., Saito, K., Yamada, N., Ohashi, Y., & Sone, H. (2013) · Diabetes Care · doi:10.2337/dc12-0783 · Cited by 212
The Effect of Giving Global Coronary Risk Information to Adults: A Systematic Review
Sheridan, S. L. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.516 · Cited by 208
Marma, A. K., Berry, J. D., Ning, H., Persell, S. D., & Lloyd-Jones, D. M. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.869727 · Cited by 195
Mora, S., Wenger, N. K., DeMicco, D. A., Breazna, A., Boekholdt, S. M., Arsenault, B. J., Deedwania, P., Kastelein, J. J. P., & Waters, D. D. (2012) · Circulation · doi:10.1161/circulationaha.111.088591 · Cited by 177
Self-citationRay, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Ridker, P. M., & Braunwald, E. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.181735 · Cited by 170
Self-citationPhysical Activity, Physical Fitness, and Hypertension
&NA; (1993) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-199310000-00024 · Cited by 147
Kirchhof, P. F., Medicine, E. C. R. A. E. A. W. S. O. P., Sipido, K. R., Medicine, E. C. R. A. E. A. W. S. O. P., Cowie, M., Medicine, E. C. R. A. E. A. W. S. O. P., Eschenhagen, T., Medicine, E. C. R. A. E. A. W. S. O. P., Fox, K. A. A., Medicine, E. C. R. A. E. A. W. S. O. P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu312 · Cited by 102
Rodríguez, F., Cannon, C. P., Steg, P. G., Kumbhani, D. J., Goto, S., Smith, S. C., Eagle, K. A., Ohman, E. M., Umez-Eronini, A. A., Hoffman, E., et al. (2013) · Clinical Cardiology · doi:10.1002/clc.22217 · Cited by 94
How to translate clinical trial results into gain in healthy life expectancy for individual patients
Dorresteijn, J. A. N., Kaasenbrood, L., Cook, N. R., van Kruijsdijk, R. C. M., van der Graaf, Y., Visseren, F. L. J., & Ridker, P. M. (2016) · BMJ · doi:10.1136/bmj.i1548 · Cited by 64
Self-citationKranenburg, G., van der Graaf, Y., van der Leeuw, J., Nathoe, H. M., de Borst, G. J., Kappelle, L. J., Visseren, F. L. J., & Westerink, J. (2015) · Diabetes Care · doi:10.2337/dc15-0493 · Cited by 53
Self-citationvan de Woestijne, A. P., van der Graaf, Y., Liem, A. H., Cramer, M. J., Westerink, J., & Visseren, F. L. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.101 · Cited by 47
Self-citationDorresteijn, J. A. N., Boekholdt, S. M., van der Graaf, Y., Kastelein, J. J. P., LaRosa, J. C., Pedersen, T. R., DeMicco, D. A., Ridker, P. M., Cook, N. R., & Visseren, F. L. J. (2013) · Circulation · doi:10.1161/circulationaha.112.000712 · Cited by 43
Self-citationWong, N. D., Dede, J., Chow, V. H., Wong, K. S., & Franklin, S. S. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2012.2 · Cited by 42
Ducrocq, G., Bhatt, D. L., Labreuche, J., Corbalan, R. L., Porath, A., Gao, R., Панченко, Е. П., Cs, L., Ikeda, Y., Goto, S., et al. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313501278 · Cited by 31
Self-citationInvestigational therapies for the treatment of atherosclerosis
TOMKIN, G. H., & Owens, D. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.922950 · Cited by 10
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Self-citation2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Self-citation2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixido-Tura, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., De Backer, J., Deglise, S., Della Corte, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 993
Self-citation2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Self-citationLechner, K., von Schacky, C., McKenzie, A. L., Worm, N., Nixdorff, U., Lechner, B., Kränkel, N., Halle, M., Krauss, R. M., & Scherr, J. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319869400 · Cited by 371
Metadata
- Authors
- Kaasenbrood, L., Boekholdt, S. M., van der Graaf, Y., Ray, K. K., Peters, R. J. G., Kastelein, J. J. P., Amarenco, P., LaRosa, J. C., Cramer, M. J. M., Westerink, J., Kappelle, L. J., de Borst, G. J., & Visseren, F. L. J.
- Venue
- Circulation
- Published
- 2016-11-08
- Volume
- 134
- Issue
- 19
- Pages
- 1419-1429
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2552653484
- Cited by
- 279
- References
- 42
- FWCI
- 21.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.